z-logo
open-access-imgOpen Access
Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma
Author(s) -
Phei Er Saw,
Xiaoding Xu,
Bo Kang,
Jungsul Lee,
Yeo Song Lee,
Chungyeul Kim,
Hyungsin Kim,
ShinHyuk Kang,
Yoo Jin Na,
Hong Joo Moon,
Joo Han Kim,
Youn-Kwan Park,
Won Ki Yoon,
Jong Hyun Kim,
Taek-Hyun Kwon,
Chulhee Choi,
Sangyong Jon,
Kyuha Chong
Publication year - 2021
Publication title -
theranostics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.689
H-Index - 97
ISSN - 1838-7640
DOI - 10.7150/thno.44948
Subject(s) - fibronectin , in vivo , glioma , cancer research , cancer , microarray , biomarker , tissue microarray , docetaxel , chemistry , extracellular matrix , medicine , microbiology and biotechnology , biology , gene expression , gene , biochemistry
Extra-domain B of fibronectin (EDB-FN) is an alternatively spliced form of fibronectin with high expression in the extracellular matrix of neovascularized tissues and malignant cancer cells. In this study, we evaluated the practicality of using EDB-FN as a biomarker and therapeutic target for malignant gliomas (MGs), representative intractable diseases involving brain tumors. Methods: The microarray- and sequence-based patient transcriptomic database 'Oncopression' and tissue microarray of MG patient tissue samples were analyzed. EDB-FN data were extracted and evaluated from 23,344 patient samples of 17 types of cancer to assess its effectiveness and selectivity as a molecular target. To strengthen the results of the patient data analysis, the utility of EDB-FN as a molecular marker and target for MG was verified using active EDB-FN-targeting ultrasmall lipidic micellar nanoparticles (~12 nm), which had a high drug-loading capacity and were efficiently internalized by MG cells in vitro and in vivo . Results: Brain tumors had a 1.42-fold cancer-to-normal ratio ( p < 0.0001), the second highest among 17 cancers after head and neck cancer. Patient tissue microarray analysis showed that the EDB-FN high-expression group had a 5.5-fold higher risk of progression than the EDB-FN low-expression group ( p < 0.03). By labeling docetaxel-containing ultrasmall micelles with a bipodal aptide targeting EDB-FN (termed APT EDB -DSPE-DTX), we generated micelles that could specifically bind to MG cells, leading to superior antitumor efficacy of EDB-FN-targeting nanoparticles compared to nontargeting controls. Conclusions: Taken together, these results show that EDB-FN can be an effective drug delivery target and biomarker for MG.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here